NASDAQ:LBRX LB Pharmaceuticals Q3 2025 Earnings Report $42.47 +0.33 (+0.78%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$43.48 +1.02 (+2.39%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast LB Pharmaceuticals EPS ResultsActual EPS-$0.61Consensus EPS -$0.57Beat/MissMissed by -$0.04One Year Ago EPSN/ALB Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALB Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) LB Pharmaceuticals Earnings HeadlinesLB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion OpportunitySeptember 18 at 5:00 AM | seekingalpha.comLB Pharmaceuticals Appoints Susan Kozauer As CMOSeptember 15, 2026 | rttnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical OfficerSeptember 15, 2026 | markets.businessinsider.comLB Pharmaceuticals Appoints Susan G. Kozauer, M.D.September 15, 2026 | globenewswire.comIPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?September 9, 2026 | investors.comSee More LB Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LB Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LB Pharmaceuticals and other key companies, straight to your email. Email Address About LB PharmaceuticalsLB Pharmaceuticals (NASDAQ:LBRX), Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious neuropsychiatric disorders. The company’s lead product candidate, LB-102, is a long-acting injectable antipsychotic being developed for the treatment of schizophrenia. LB-102 is designed to provide sustained delivery of its active pharmaceutical ingredient and potentially support adherence compared with daily oral therapies. LB Pharmaceuticals is evaluating the candidate through clinical development intended to assess its safety, tolerability, pharmacokinetics and effectiveness in people with schizophrenia. The company’s activities are centered on advancing its pipeline through clinical trials and regulatory development. Publicly available information about LB Pharmaceuticals’ broader product portfolio, geographic operations and leadership is limited.View LB Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
